Lenalidomide for the treatment of relapsed and refractory multiple myeloma

References

• KotlaVGoelSNischalSMechanism of action of lenalidomide in hematological malignanciesJ Hematol Oncol200923619674465
   PubMed Web of Science ®Google Scholar
• ValletSWitzens-HarigMJaegerDPodarKUpdate on immunomodulatory drugs (IMiDs) in hematologic and solid malignanciesExpert Opin Pharmacother201213447349422324734
   PubMed Web of Science ®Google Scholar
• DaviesFBazRLenalidomide mode of action: linking bench and clinical findingsBlood Rev201024 Suppl 1S13S1921126632
   PubMed Web of Science ®Google Scholar
• RichardsonPGSchlossmanRLWellerEImmunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood200210093063306712384400
   PubMed Web of Science ®Google Scholar
• HideshimaTChauhanDShimaYThalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapyBlood20009692943295011049970
   PubMed Web of Science ®Google Scholar
• MitsiadesNMitsiadesCSPoulakiVApoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implicationsBlood200299124525453012036884
   PubMed Web of Science ®Google Scholar
• VerhelleDCorralLGWongKLenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cellsCancer Res200767274675517234786
   PubMed Web of Science ®Google Scholar
• JakubikovaJAdamiaSKost-AlimovaMLenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implicationsBlood2011117174409441921321360
   PubMed Web of Science ®Google Scholar
• ItoTAndoHSuzukiTIdentification of a primary target of thalidomide teratogenicityScience201032759711345135020223979
   PubMed Web of Science ®Google Scholar
• ZhuYXBraggioEShiCXCereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomideBlood2011118184771477921860026
   PubMed Web of Science ®Google Scholar
• GeitzHHandtSZwingenbergerKThalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascadeImmunopharmacology1996312–32132218861747
   PubMed Web of Science ®Google Scholar
• HideshimaTChauhanDSchlossmanRRichardsonPAndersonKCThe role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applicationsOncogene200120334519452711494147
   PubMed Web of Science ®Google Scholar
• CorralLGHaslettPAMullerGWDifferential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alphaJ Immunol1999163138038610384139
   PubMed Web of Science ®Google Scholar
• GuptaDTreonSPShimaYAdherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applicationsLeukemia200115121950196111753617
   PubMed Web of Science ®Google Scholar
• De LuisiAFerrucciAColucciaAMLenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myelomaClin Cancer Res20111771935194621307145
   PubMed Web of Science ®Google Scholar
• BreitkreutzIRaabMSValletSLenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myelomaLeukemia200822101925193218596740
   PubMed Web of Science ®Google Scholar
• DaviesFERajeNHideshimaTThalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myelomaBlood200198121021611418482
   PubMed Web of Science ®Google Scholar
• ChangDHLiuNKlimekVEnhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implicationsBlood2006108261862116569772
   PubMed Web of Science ®Google Scholar
• GalustianCMeyerBLabartheMCThe anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cellsCancer Immunol Immunother20095871033104519009291
   PubMed Web of Science ®Google Scholar
• MullerGWChenRHuangSYAmino-substituted thalidomide analogs: potent inhibitors of TNF-alpha productionBioorg Med Chem Lett19999111625163010386948
   PubMed Web of Science ®Google Scholar
• LeBlancRHideshimaTCatleyLPImmunomodulatory drug costimulates T cells via the B7-CD28 pathwayBlood200410351787179014512311
   PubMed Web of Science ®Google Scholar
• GorgunGCalabreseESoydanEImmunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myelomaBlood2010116173227323720651070
   PubMed Web of Science ®Google Scholar
• RichardsonPGBloodEMitsiadesCSA randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myelomaBlood2006108103458346416840727
   PubMed Web of Science ®Google Scholar
• RichardsonPJagannathSHusseinMSafety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myelomaBlood2009114477277819471019
   PubMed Web of Science ®Google Scholar
• DimopoulosMSpencerAAttalMfor Multiple Myeloma (010) Study InvestigatorsLenalidomide plus dexamethasone for relapsed or refractory multiple myelomaN Engl J Med2007357212123213218032762
   PubMed Web of Science ®Google Scholar
• WeberDMChenCNiesvizkyRfor Multiple Myeloma (009) Study InvestigatorsLenalidomide plus dexamethasone for relapsed multiple myeloma in North AmericaN Engl J Med2007357212133214218032763
   PubMed Web of Science ®Google Scholar
• DimopoulosMAChenCSpencerALong-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myelomaLeukemia200923112147215219626046
   PubMed Web of Science ®Google Scholar
• HarousseauJLDimopoulosMAWangMBetter quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myelomaHaematologica201095101738174420460639
   PubMed Web of Science ®Google Scholar
• San-MiguelJFDimopoulosMAStadtmauerEAEffects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasoneClin Lymphoma Myeloma Leuk2011111384321273172
   PubMed Web of Science ®Google Scholar
• San MiguelJDimopoulosMBravoMLWeberDLonger duration of treatment and maintenance of best response with lenalidomide + dexamethasone increases overall survival (OS) in patients with relapsed/refractory multiple myeloma [abstract]Haematologica200994Suppl 2382
   Google Scholar
• San MiguelJFDimopoulosMWeberDDexamethasone dose adjustments seem to result in better efficacy and improved tolerability in patients with relapsed/refractory multiple myeloma who are treated with lenalidomide/dexamethasone (MM009/010 sub-analysis) [abstract]Blood (ASH Annual Meeting Abstracts)2007110112712
   Web of Science ®Google Scholar
• RajkumarSVJacobusSCallanderNSfor Eastern Cooperative Oncology GroupLenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trialLancet Oncol2010111293719853510
   PubMed Web of Science ®Google Scholar
• DimopoulosMAHusseinMSwernASWeberDImpact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myelomaLeukemia201125101620162621747400
   PubMed Web of Science ®Google Scholar
• StadtmauerEAWeberDMNiesvizkyRLenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myelomaEur J Haematol200982642643219302559
   PubMed Web of Science ®Google Scholar
• WangMDimopoulosMAChenCLenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposureBlood2008112124445445118799726
   PubMed Web of Science ®Google Scholar
• Avet-LoiseauHSoulierJFermandJPfor IFM MAG groupsImpact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasoneLeukemia201024362362820072152
   PubMed Web of Science ®Google Scholar
• GuglielmelliTBringhenSRrodheSPrevious thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patientsEur J Cancer201147681481821334196
   PubMed Web of Science ®Google Scholar
• KneppersELokhorstHMEeltinkCMAnalysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use programClin Lymphoma Myeloma Leuk201010213814320371448
   PubMed Web of Science ®Google Scholar
• MateosMVRichardsonPGSchlagRBortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trialJ Clin Oncol201028132259226620368561
   PubMed Web of Science ®Google Scholar
• ReeceDSongKWFuTInfluence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13Blood2009114352252519332768
   PubMed Web of Science ®Google Scholar
• KleinUNebenKHielscherTHeissCHoADGoldschmidtHLenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairmentAnn Hematol201190442943920857112
   PubMed Web of Science ®Google Scholar
• ChangHJiangAQiCTrieuYChenCReeceDImpact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasoneLeuk Lymphoma201051112084209120929319
   PubMed Web of Science ®Google Scholar
• KnopSGereckeCLiebischPLenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)Blood2009113184137414319182205
   PubMed Web of Science ®Google Scholar
• BazRWalkerEKaramMALenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacyAnn Oncol200617121766177116980599
   PubMed Web of Science ®Google Scholar
• LentzschSO’SullivanAKennedyRCombination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with refractory or relapsed multiple myeloma is safe and highly effective: results of phase I/II open-label, dose escalation study [abstract]Blood (ASH Annual Meeting Abstracts)201111821304
   Web of Science ®Google Scholar
• PonischWHeynSWagnerICombined bendamustine, prednisolone and lenalidomide (RBP) in refractory or relapsed multiple myeloma. First results of a phase I clinical trial [abstract]Blood (ASH Annual Meeting Abstracts)2010116211971
   Web of Science ®Google Scholar
• van de DonkNWWittebolSMinnemaMCLokhorstHMLenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myelomaBr J Haematol2010148233533720085583
   PubMed Web of Science ®Google Scholar
• MorganGJScheySAWuPLenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patientsBr J Haematol2007137326826917408469
   PubMed Web of Science ®Google Scholar
• ScheySAMorganGJRamasamyKThe addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II studyBr J Haematol2010150332633320553268
   PubMed Web of Science ®Google Scholar
• ReeceDEMasih-KhanEKhanAPhase I-II trial of oral cyclophosphamide, prednisone and lenalidomide (Revlimid(R)) (CPR) for the treatment of patients with relapsed and refractory multiple myeloma [abstract]Blood (ASH Annual Meeting Abstracts)2010116213055
   Web of Science ®Google Scholar
• RichardsonPGWellerEJagannathSMulticenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myelomaJ Clin Oncol200927345713571919786667
   PubMed Web of Science ®Google Scholar
• RichardsonPGJagannathSJakubowiakAJPhase II trial of lenalidomide, bortezomib, and dexamethasone in patients (pts) with relapsed and relapsed/refractory multiple myeloma (MM): updated efficacy and safety data after >2 years of follow-up [abstract]Blood (ASH Annual Meeting Abstracts)2010116213049
   Google Scholar
• DimopoulosMAKastritisEChristoulasDTreatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapiesLeukemia201024101769177820739955
   PubMed Web of Science ®Google Scholar
• BelhadjKAmraouiKSafarVLenalidomide plus bortezomib and dexamethasone (RVD) followed by lenalidomide plus dexamethasone as salvage treatment for myeloma patients in first relapse after autologous stem cell transplantation. Single institution experience [abstract]Blood (ASH Annual Meeting Abstracts)2011118215143
   Google Scholar
• BerensonJRYellinOCartmellADA phase II study of pegylated liposomal doxorubicin (PLD), bortezomib, dexamethasone and lenalidomide (DVD-R) for patients with relapsed/refractory (R/R) multiple myeloma (MM) [abstract]Blood (ASH Annual Meeting Abstracts)2010116213044
   Google Scholar
• NiesvizkyRWangLOrlowskiRZPhase Ib multicenter dose escalation study of carfilzomib plus lenalidomide and low dose dexamethasone (CRd) in relapsed and refractory multiple myeloma (MM) [abstract]Blood (ASH Annual Meeting Abstracts)1120200911422304
   Web of Science ®Google Scholar
• PalumboALaroccaAFalcoPLenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myelomaLeukemia20102451037104220376079
   PubMed Web of Science ®Google Scholar
• ShahJJOrlowskiRZAlexanianRPhase I trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed/refractory multiple myeloma [abstract]Blood (ASH Annual Meeting Abstracts)2010116211948
   Google Scholar
• RajeNKumarSHideshimaTCombination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myelomaBlood2004104134188419315319277
   PubMed Web of Science ®Google Scholar
• HofmeisterCCYangXPichiorriFPhase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoproteinJ Clin Oncol201129253427343421825263
   PubMed Web of Science ®Google Scholar
• MahindraARichardsonPGHariPUpdated results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma with pharmacodynamic and pharmacokinetic analysis [abstract]Blood (ASH Annual Meeting Abstracts)2010116213051
   Web of Science ®Google Scholar
• RichardsonPWeberDMitsiadesCSA phase I study of vorinostat, lenalidomide, and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: excellent tolerability and promising activity in a heavily pretreated population [abstract]Blood (ASH Annual Meeting Abstracts)2010116211951
   Google Scholar
• RichterJRBilottiEMcBrideLSalvage therapy with vorinostat, lenalidomide, and dexamethasone (ZRD) in lenalidomide/dexamethasone relapsed/refractory multiple myeloma [abstract]Blood (ASH Annual Meeting Abstracts)2011118213986
   Web of Science ®Google Scholar
• JakubowiakAJRichardsonPGZimmermanTMFinal phase I results of perifosine in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (MM) [abstract]Blood (ASH Annual Meeting Abstracts)2010116213064
   PubMed Web of Science ®Google Scholar
• QuachHRitchieDStewartAKMechanism of action of immunomodulatory drugs (IMiDS) in multiple myelomaLeukemia2010241223219907437
   PubMed Web of Science ®Google Scholar
• HayashiTHideshimaTAkiyamaMMolecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical applicationBr J Haematol2005128219220315638853
   PubMed Web of Science ®Google Scholar
• van de DonkNWKampsSMutisTLokhorstHMMonoclonal antibody-based therapy as a new treatment strategy in multiple myelomaLeukemia201226219921321852787
   PubMed Web of Science ®Google Scholar
• LonialSJakubowiakAJJagannathSA phase 2 study of elotuzumab in combination with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma [abstract]Blood (ASH Annual Meeting Abstracts)201111821303
   Web of Science ®Google Scholar
• LonialSVijRHarousseauJLElotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myelomaJ Clin Oncol201230161953195922547589
   PubMed Web of Science ®Google Scholar
• BerdejaJGAilawadhiSNiesvizkyRPhase I study of lorvotuzumab mertansine (IMGN901) in combination with lenalidomide and dexamethasone in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma – a preliminary safety and efficacy analysis of the combination [abstract]Blood (ASH Annual Meeting Abstracts)2010116211934
   Web of Science ®Google Scholar
• AguraENiesvizkyRMatousJDacetuzumab (SGN-40), lenalidomide, and weekly dexamethasone in relapsed or refractory multiple myeloma: multiple responses observed in a phase 1b study [abstract]Blood (ASH Annual Meeting Abstracts)2009114222870
   Web of Science ®Google Scholar
• ZhangSLiangJChenLEnhanced NK cell mediated cytotoxicity against multiple myeloma (MM) cells by the combination of anti-KIR (1-7F9) monoclonal antibody (mAb) and lenalidomide [abstract]AACR Meeting Abstracts20092_Annual_Meeting3245
   Google Scholar
• SakamakiIKaplanBChaS-CQinHKwakLWPotent immunomodulatory effects of lenalidomide on effector T cells and Treg improve the effectiveness of a therapeutic lymphoma vaccine [abstract]Blood (ASH Annual Meeting Abstracts)201111821108
   Web of Science ®Google Scholar
• LuptakovaKGlotzbeckerBMillsHLenalidomide decreases PD-1 expression, depletes regulatory T-cells and improves cellular response to a multiple myeloma/dendritic cell fusion vaccine in vitro [abstract]Blood (ASH Annual Meeting Abstracts)201011621492
   Web of Science ®Google Scholar
• NoonanKRudrarajuLFergusonALenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responsesClin Cancer Res20121851426143422241792
   PubMed Web of Science ®Google Scholar
• van de DonkNWKrogerNHegenbartURemarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myelomaBlood200610783415341616597603
   PubMed Web of Science ®Google Scholar
• KrogerNBadbaranALioznovMPost-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myelomaExp Hematol200937779179819487069
   PubMed Web of Science ®Google Scholar
• MinnemaMCvan der VeerMSAartsTEmmelotMMutisTLokhorstHMLenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cellsLeukemia200923360560718784738
   PubMed Web of Science ®Google Scholar
• KneppersEvan der HoltBKerstenMJLenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 TrialBlood201111892413241921690556
   PubMed Web of Science ®Google Scholar
• El-CheikhJCrocchioloRFurstSLenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myelomaExp Hematol201240752152722446605
   PubMed Web of Science ®Google Scholar
• KumarSKRajkumarSVDispenzieriAImproved survival in multiple myeloma and the impact of novel therapiesBlood200811152516252017975015
   PubMed Web of Science ®Google Scholar
• PalumboAAndersonKMultiple myelomaN Engl J Med2011364111046106021410373
   PubMed Web of Science ®Google Scholar
• PalumboABringhenSLudwigHPersonalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)Blood2011118174519452921841166
   PubMed Web of Science ®Google Scholar
• QuachHFernyhoughLHendersonRLower-dose lenalidomide and dexamethasone reduces toxicity without compromising efficacy in patients with relapsed/refractory myeloma, who are aged ≥60 years or have renal impairment: planned interim results of a prospective multicentre phase II trial [abstract]Blood (ASH Annual Meeting Abstracts)2010116211961
   Google Scholar
• DimopoulosMATerposEGoldschmidtHAlegreAMarkTNiesvizkyRTreatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairmentCancer Treat Rev5182012 [Epub ahead of print.]
   Web of Science ®Google Scholar
• NiesvizkyRNaibTChristosPJLenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naive patients undergoing front-line lenalidomide and dexamethasone therapyBr J Haematol2007138564064317686058
   PubMed Web of Science ®Google Scholar
• DimopoulosMAlegreAStadtmauerEAThe efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal functionCancer2010116163807381420564094
   PubMed Web of Science ®Google Scholar
• KleberMIhorstGUdiJKochBWaschREngelhardtMPrognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisalClin Lymphoma Myeloma Leuk2012121384822054851
   PubMed Web of Science ®Google Scholar
• DimopoulosMAChristoulasDRoussouMLenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairmentEur J Haematol20108511520192988
   PubMed Web of Science ®Google Scholar
• de la RubiaJRoigMIbanezAActivity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective studyEur J Haematol201085436336520662900
   PubMed Web of Science ®Google Scholar
• PalumboABladeJBoccadoroMHow to manage neutropenia in multiple myelomaClin Lymphoma Myeloma Leuk201212151122178143
   PubMed Web of Science ®Google Scholar
• BennettCLAngelottaCYarnoldPRThalidomide- and lenalidomide-associated thromboembolism among patients with cancerJAMA2006296212558256017148721
   PubMed Web of Science ®Google Scholar
• ZonderJABarlogieBDurieBGMcCoyJCrowleyJHusseinMAThrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxisBlood20061081403 author reply 40416790586
   PubMed Web of Science ®Google Scholar
• KnightRDeLapRJZeldisJBLenalidomide and venous thrombosis in multiple myelomaN Engl J Med2006354192079208016687729
   PubMed Web of Science ®Google Scholar
• PalumboARajkumarSVDimopoulosMAfor International Myeloma Working GroupPrevention of thalidomide- and lenalidomide-associated thrombosis in myelomaLeukemia200822241442318094721
   PubMed Web of Science ®Google Scholar
• LaroccaACavalloFBringhenSAspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomideBlood20121194933939 quiz 109321835953
   PubMed Web of Science ®Google Scholar
• LonialSRichardsonPGSan MiguelJCharacterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myelomaBr J Haematol2008143222222918713253
   PubMed Web of Science ®Google Scholar
• Pineda-RomanMZangariMvan RheeFVTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myelomaLeukemia20082271419142718432260
   PubMed Web of Science ®Google Scholar
• CiolliSLeoniFCasiniCBreschiCSantiniVBosiAThe addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myelomaBr J Haematol2008141681481918410447
   PubMed Web of Science ®Google Scholar
• CiolliSLeoniFGigliFRigacciLBosiALow dose Velcade, thalidomide and dexamethasone (LD-VTD): an effective regimen for relapsed and refractory multiple myeloma patientsLeuk Lymphoma200647117117316321846
   PubMed Web of Science ®Google Scholar
• PalumboAAmbrosiniMTBenevoloGfor Italian Multiple Myeloma Network, Gruppo Italiano Malattie Ematologicche dell’AdultoBortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myelomaBlood200710972767277217148584
   PubMed Web of Science ®Google Scholar
• TerposEKastritisERoussouMThe combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesisLeukemia200822122247225618769451
   PubMed Web of Science ®Google Scholar
• ZangariMFinkLZhanFTricotGLow venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimensClin Lymphoma Myeloma Leuk201111222823621575928
   PubMed Web of Science ®Google Scholar
• ZangariMTricotGPolavaramLSurvival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasoneJ Clin Oncol201028113213519901114
   PubMed Web of Science ®Google Scholar
• RajkumarSVHaymanSRLacyMQCombination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myelomaBlood2005106134050405316118317
   PubMed Web of Science ®Google Scholar
• KleinUKoselyFHillengassJEffective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasoneAnn Hematol2009881677118668241
   PubMed Web of Science ®Google Scholar
• PalumboADelforgeMCatalanoJA phase 3 study evaluating the efficacy and safety of lenalidomide combined with melphalan and prednisone In patients ≥ 65 years with newly diagnosed multiple myeloma (NDMM): continuous use of lenalidomide vs fixed-duration regimens [abstract]Blood (ASH Annual Meeting Abstracts)201011621622
   Web of Science ®Google Scholar
• PalumboAHajekRDelforgeMfor MM-015 InvestigatorsContinuous lenalidomide treatment for newly diagnosed multiple myelomaN Engl J Med2012366191759176922571200
   PubMed Web of Science ®Google Scholar
• AttalMLauwersVcMaritGMaintenance treatment with lenalidomide after transplantation for MYELOMA: final analysis of the IFM 2005–2002 [abstract]Blood (ASH Annual Meeting Abstracts)201011621310
   Web of Science ®Google Scholar
• McCarthyPOwzarKAndersonKPhase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB ECOG BMT-CTN 100104Haematologica201196s1S23
   Google Scholar
• AttalMLauwers-CancesVMaritGfor IFM InvestigatorsLenalidomide maintenance after stem-cell transplantation for multiple myelomaN Engl J Med2012366191782179122571202
   PubMed Web of Science ®Google Scholar
• McCarthyPLOwzarKHofmeisterCCLenalidomide after stem-cell transplantation for multiple myelomaN Engl J Med2012366191770178122571201
   PubMed Web of Science ®Google Scholar
• DimopoulosMARichardsonPGBrandenburgNA review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomideBlood2012119122764276722323483
   PubMed Web of Science ®Google Scholar
• DimopoulosMAPalumboAAttalMfor European Myeloma NetworkOptimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statementLeukemia201125574976021293488
   PubMed Web of Science ®Google Scholar
• BarosiGMerliniGBillioASIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myelomaAnn Hematol201291687588822476884
   PubMed Web of Science ®Google Scholar
• KumarSKLeeJHLahuertaJJfor International Myeloma Working GroupRisk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group studyLeukemia201226114915721799510
   PubMed Web of Science ®Google Scholar
• van de DonkNWLokhorstHMDimopoulosMTreatment of relapsed and refractory multiple myeloma in the era of novel agentsCancer Treat Rev201137426628320863623
   PubMed Web of Science ®Google Scholar